Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population

Li, Wen; Deng, Jing; Jiang, Pei; Tang, Jianxin

doi:10.4161/cbt.10.10.13231

Cited by 15 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, detection of aberrant methylation of FHIT gene would be useful for lung cancer diagnosis. Our results demonstrated the strong statistically significant differences of FHIT promoter methylation status between lung cancer patients and controls (P = .002), and the results were similar to previous reports [31].…”

Section: Discussionsupporting

confidence: 94%

“…Previous studies reported different results on the association analysis between p16, RASSF1A, and FHIT genes methylation and clinic pathological characteristics. In the present study, the results were similar to previous reports [18,28,[31][32][33] and no statistical difference was confirmed. Some previous studies, on the contrary, reported that old age, smoking, and histology type as bearing strong correlations with the p16, RASSF1A, or FHIT genes methylation change [18,25,[34][35][36][37].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood

Tan

Sun

Wei

et al. 2013

Experimental Lung Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 90%

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood

Tan

Sun

Wei

et al. 2013

Experimental Lung Research

View full text Add to dashboard Cite

show abstract

“…Forty two of those were excluded due to laboratory studies, non-original articles (review), or studies irrelevant to the current analysis. Eventually, there were sixteen studies included in final meta-analysis 16 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 as shown in Fig. 1 .…”

Section: Resultsmentioning

confidence: 99%

The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review

Yan

Han

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Emerging evidence indicates that FHIT is a candidate tumor suppressor in non-small cell lung cancer (NSCLC). However, the correlation between FHIT hypermethylation and clinicopathological characteristics of NSCLC remains unclear. Thus, we conducted a meta-analysis to quantitatively evaluate the effects of FHIT hypermethylation on the incidence of NSCLC and clinicopathological characteristics. Final analysis of 1717 NSCLC patients from 16 eligible studies was performed. FHIT hypermethylation was found to be significantly higher in NSCLC than in normal lung tissue, the pooled OR from 8 studies including 735 NSCLC and 708 normal lung tissue, OR = 5.45, 95% CI = 2.15–13.79, p = 0.0003. FHIT hypermethylation was also correlated with sex status, smoking status, as well as pathological types. We did not find that FHIT hypermethylation was correlated with the differentiated types or clinical stages in NSCLC patients. However, patients with FHIT hypermethylation had a lower survival rate than those without, HR = 1.73, 95% CI = 1.10–2.71, p = 0.02. The results of this meta-analysis suggest that FHIT hypermethylation is associated with an increased risk and worsen survival in NSCLC patients. FHIT hypermethylation, which induces the inactivation of FHIT gene, plays an important role in the carcinogenesis and clinical outcome and may serve as a potential drug target of NSCLC.

show abstract

“…The five-year survival rate of lung cancer patients is 13%. A crucial reason for this is that lung cancer has often already metastasized at the time of detection, rendering the long-term prognosis as poor (2). Therefore, early diagnosis of lung cancer is a realistic approach in reducing mortality associated with lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Detection of lung cancer with blood microRNA-21 expression levels in Chinese population

Ouyang

et al. 2011

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Abstract. The analysis of molecular markers in the biological field has been proposed as a useful tool for cancer diagnosis. MicroRNAs (miRNAs) may regulate diverse biological processes and play a significant role in tumorigenesis. The potential use of blood-based miRNAs as a biomarker of cancer and as a target for therapeutics is promising. The purpose of this study was to determine whether aberrant miRNA expression can be used as a molecular marker in peripheral blood for the diagnosis of lung cancer. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to analyze the expression levels of mature microRNA-21 (miR-21). Blood samples from 20 lung cancer patients and 10 healthy individuals were collected. The data were compared for the diagnosis of lung cancer. The results demonstrated that miR-21 was present in the peripheral blood in a markedly stable form and could be detected by real-time PCR sensitively and specifically. A significant difference was observed between the lung cancer cases and controls regarding miR-21 levels in peripheral blood (1947.26±930.56 pg/ml vs. 943.42±314.12 pg/ml, P=0.005). Furthermore, the overexpression of miR-21 showed a highly discriminative receiver operating characteristic (ROC) curve profile, clearly distinguishing cancer patients from cancer-free subjects with an area under the ROC curve (AUROC) of 0.912±0.045. The detection of miR-21 expression yielded 78.80% sensitivity and 100.00% specificity in the diagnosis of lung cancer. These findings indicate that in peripheral blood miR-21 may serve as a potential molecular marker for lung cancer and provide a new approach in the diagnosis of lung cancer. IntroductionLung cancer is the leading cause of cancer death in China and worldwide (1). The five-year survival rate of lung cancer patients is 13%. A crucial reason for this is that lung cancer has often already metastasized at the time of detection, rendering the long-term prognosis as poor (2). Therefore, early diagnosis of lung cancer is a realistic approach in reducing mortality associated with lung cancer. Although advanced technology, such as computed tomography (CT), positron emission tomography (PET) and X-ray appear to be promising methods of detection, technology is not capable of precisely realizing the early detection of lung cancer. The development of diagnostic tools is necessary for the early detection of lung cancer (3,4).MicroRNAs (miRNAs) are a class of small RNAs (~21-24 nt in length) that are capable of post-transcriptionally regulating hundreds of target genes, thereby controlling a wide variety of biological processes, including cell growth, proliferation, differentiation and apoptosis (5). Furthermore, miRNA expression is involved in cancer development and progression as a tumor suppressor or oncogene (6,7). Aberrant miRNA expression as a biomarker provides a new approach to improving the accuracy of the early diagnosis of lung cancer. However, miRNA expression pattern biomarkers for disease management, personalized therapy, d...

show abstract

Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population

Cited by 15 publications

References 23 publications

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood

The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review

Detection of lung cancer with blood microRNA-21 expression levels in Chinese population

Contact Info

Product

Resources

About